An 8 Week Phase Ib, Monocentric, Randomized, Double-masked, Parallel Groups, Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of a 180 μg/ml rhNGF Eye Drops Solution Vs Vehicle in Patients With Glaucoma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Cenegermin (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- Acronyms NGF-Glaucoma
- Sponsors Dompe Farmaceutici
- 19 Jul 2018 Status changed from recruiting to completed.
- 23 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
- 23 Jan 2017 Status changed from not yet recruiting to recruiting.